Silexion Therapeutics Ltd.
SLXNNASDAQHealthcareBiotechnology
Previous close
$0.3941
−$0.0049 · -1.23%
SLXN company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
43
Fair Value
Momentum
17
Strong Down
Sentiment
53
Mixed
Risk resilience
37
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteSilexion Therapeutics LTD is a biopharmaceutical company specializing in the discovery and advancement of RNA interference (RNAi)-based cancer therapies and their associated delivery systems, with a focus on treating aggressive solid tumors. The company's strategy for addressing these tumors relies on its proprietary LODER delivery platform. Its product pipeline features several key candidates: SiG12D-LODER, which has progressed through both preclinical studies and an open-label Phase I clinical trial for pancreatic cancer; Prostate-LODER, currently undergoing preclinical evaluation for prostate cancer; and GBM-LODER, also in preclinical development, targeting Glioblastoma Multiforme, a highly malignant primary brain tumor. Founded in 2008, Silexion Therapeutics is headquartered in Jerusalem, Israel.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- IL
- CEO
- Ilan Hadar
- Listed since
- Aug 16, 2024
- Employees
- 14
Market position
Day range
Current $0.3941
52-week range
Current $0.3941
- Open
- $0.389
- Previous close
- $0.399
- Volume
- 226.98K
- 0.4× average
- Average volume
- 562.54K
- Average daily volume
- Market cap
- 165.13K USD
- Beta
- -0.25
- Market reference 1
- 50-day average
- $2.1083
- -81.31% below average
- 200-day average
- $12.8391
- -96.93% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- -2.97M USD
- P/E (TTM)
- -0.01×
- P/B (TTM)
- 6.16×
- P/S (TTM)
- 0×
- EV / EBITDA
- 0.25×
- Earnings yield
- -466.65%
- Free cash flow yield
- -424.19%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- -457.63%
- Return on assets
- -165.10%
- Return on invested capital
- 250.74%
Financial health
- Debt / equity
- 32.05×
- Current ratio
- 2.41×
- Altman Z-score
- -31.25
- Piotroski F-score
- 1 of 9
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 7.14M USD | 5.82M USD | 3.71M USD | 3.23M USD | — |
| Selling, general, and administrative | 4.48M USD | 6.73M USD | 928K USD | 577K USD | 943.93K USD |
| Operating expenses | −11.63M USD | 12.57M USD | 4.68M USD | 3.86M USD | 943.93K USD |
| Interest income | 142K USD | 1K USD | 153K USD | 114K USD | 6.37K USD |
| Interest expense | 13K USD | 52K USD | 9K USD | 85K USD | — |
| Depreciation and amortization | 14K USD | 25K USD | 45K USD | 57K USD | — |
| Operating income | 11.63M USD | −12.57M USD | −4.68M USD | −3.86M USD | −943.93K USD |
| Net income | −11.91M USD | −16.44M USD | −4.94M USD | −3.22M USD | −755.22K USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 50%
- 4 beats, 4 misses, 0 met estimates
- Average EPS surprise
- -230.94%
- 8 comparable reports
- Latest EPS result
- -5.17
- Estimate -21.2 · Beat by 75.61%
EPS: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Recent analyst actions
SLXN news
Corporate actions
Corporate action history
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | May 29, 2026 | 1:10 | — | — |
Stock split | Jul 29, 2025 | 1:15 | — | — |
Stock split | Nov 29, 2024 | 1:9 | — | — |
Effective May 29, 2026
1:10
Effective Jul 29, 2025
1:15
Effective Nov 29, 2024
1:9
SLXN peers
Continue in GoAI
Research SLXNresearch.disclaimer